Andersen-Tawil syndrome laboratory findings

Jump to navigation Jump to search

Andersen-Tawil syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Differentiating Andersen-Tawil syndrome from other Diseases

Epidemiology and Demographics

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Tertiary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Andersen-Tawil syndrome laboratory findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

slides

Images

American Roentgen Ray Society Images of Andersen-Tawil syndrome laboratory findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Andersen-Tawil syndrome laboratory findings

CDC on Andersen-Tawil syndrome laboratory findings

Andersen-Tawil syndrome laboratory findings in the news

Blogs on Andersen-Tawil syndrome laboratory findings

Directions to Hospitals Treating Andersen-Tawil syndrome

Risk calculators and risk factors for Andersen-Tawil syndrome laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vamsikrishna Gunnam M.B.B.S [2]

Overview

Laboratory findings consistent with the diagnosis of Andersen-Tawil syndrome (ATS) include serum potassium levels. Some patients with Andersen-Tawil syndrome (ATS) may have elevated/reduced concentration of serum potassium levels, which is usually suggestive of Andersen-Tawil syndrome (ATS).

Laboratory Findings

References

  1. Sansone V, Tawil R (2007). "Management and treatment of Andersen-Tawil syndrome (ATS)". Neurotherapeutics. 4 (2): 233–7. doi:10.1016/j.nurt.2007.01.005. PMID 17395133.
  2. Nguyen, Hoai-Linh; Pieper, Gerard H.; Wilders, Ronald (2013). "Andersen–Tawil syndrome: Clinical and molecular aspects". International Journal of Cardiology. 170 (1): 1–16. doi:10.1016/j.ijcard.2013.10.010. ISSN 0167-5273.
  3. Nguyen HL, Pieper GH, Wilders R (2013). "Andersen-Tawil syndrome: clinical and molecular aspects". Int J Cardiol. 170 (1): 1–16. doi:10.1016/j.ijcard.2013.10.010. PMID 24383070.
  4. Ryan DP, da Silva MR, Soong TW, Fontaine B, Donaldson MR, Kung AW; et al. (2010). "Mutations in potassium channel Kir2.6 cause susceptibility to thyrotoxic hypokalemic periodic paralysis". Cell. 140 (1): 88–98. doi:10.1016/j.cell.2009.12.024. PMC 2885139. PMID 20074522.
  5. Munir I, Mehmood T, Islam K, Soni L, McFarlane SI (2019). "Thyrotoxic Periodic Paralysis with Sensory Deficits in Young African American Male: A Case Report and Literature Review". Am J Med Case Rep. 7 (7): 138–142. doi:10.12691/ajmcr-7-7-5. PMC 6688769 Check |pmc= value (help). PMID 31404457.
  6. Rajpal A, Sood A (2019). "HYPOKALEMIC PERIODIC PARALYSIS IN A PATIENT WITH EUTHYROID GRAVES DISEASE AND CELIAC DISEASE". AACE Clin Case Rep. 5 (1): e73–e76. doi:10.4158/ACCR-2018-0206. PMC 6876974 Check |pmc= value (help). PMID 31967006.


Template:WikiDoc Sources